FreeGuest Editorial Science is winning the war on cancer—CMS shouldn’t disarm February 13, 2026Vol.52 No.06By John M. O’Brien
Guest Editorial The National Highway Traffic Safety Administration has a profound, albeit not immediately obvious, impact on cancer February 06, 2026Vol.52 No.05By Ken Kobayashi and Joan H. Schiller
Guest Editorial Blood Cancer United: A new name at the right moment January 23, 2026Vol.52 No.03By E. Anders Kolb
FreeGuest Editorial When “safe and effective” is not “reasonable and necessary”We can curb excessive drug dosing and improve the quality of cancer care January 16, 2026Vol.52 No.02By Mark J. Ratain and David A. Hyman
Guest Editorial With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025 December 19, 2025Vol.51 No.46By Richard J. Jones
Guest Editorial Mail-out colorectal cancer screening programs extend, rather than replace, clinical care December 05, 2025Vol.51 No.44By Paul J. Limburg
Guest Editorial My introduction to, and lessons learned from, Rick Pazdur November 21, 2025Vol.51 No.43By Mikkael A. Sekeres
Guest Editorial Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA November 14, 2025Vol.51 No.42By Ellen V. Sigal
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Guest Editorial How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care November 07, 2025Vol.51 No.41By Kathy Davy
